[{"id":"6496b67a-0445-408d-84b5-b4ec4d9b149e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06846463","created_at":"2025-03-03T10:04:54.767Z","updated_at":"2025-03-03T10:04:54.767Z","phase":"Phase 2","brief_title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","source_id_and_acronym":"NCT06846463","lead_sponsor":"Virginia Commonwealth University","biomarkers":" BCL2 • NOTCH1 • MYD88 • CD79B • CD5","pipe":"","alterations":" ","tags":["BCL2 • NOTCH1 • MYD88 • CD79B • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/31/2029","primary_completion_date":" 07/31/2029","study_txt":" Completion: 07/31/2032","study_completion_date":" 07/31/2032","last_update_posted":"2025-02-26"},{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"7d526185-7f46-4c4c-8f3a-7efa8cb4410a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03516617","created_at":"2021-01-18T17:18:31.951Z","updated_at":"2025-02-25T12:26:55.184Z","phase":"Phase 2","brief_title":"Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT03516617","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 03/15/2030","primary_completion_date":" 03/15/2030","study_txt":" Completion: 03/15/2031","study_completion_date":" 03/15/2031","last_update_posted":"2025-02-24"},{"id":"88783755-7459-4207-a7a6-0af081a9d60d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01496976","created_at":"2021-01-18T06:16:27.062Z","updated_at":"2025-02-25T13:48:06.671Z","phase":"Phase 2","brief_title":"Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL","source_id_and_acronym":"NCT01496976","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD20 • CD5","pipe":"","alterations":" ","tags":["CD20 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Arzerra (ofatumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/30/2012","start_date":" 03/30/2012","primary_txt":" Primary completion: 10/06/2021","primary_completion_date":" 10/06/2021","study_txt":" Completion: 03/25/2025","study_completion_date":" 03/25/2025","last_update_posted":"2025-02-21"},{"id":"e2ff7fb5-f1de-4b7f-9fd4-438675875b61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02160015","created_at":"2021-01-18T10:03:19.018Z","updated_at":"2025-02-25T13:52:04.076Z","phase":"Phase 1","brief_title":"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02160015","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 03/27/2017","primary_completion_date":" 03/27/2017","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-20"},{"id":"c70f6861-a666-4861-ad3d-2301e394ab62","acronym":"ASCEND","url":"https://clinicaltrials.gov/study/NCT02970318","created_at":"2021-01-17T17:36:01.594Z","updated_at":"2025-02-25T14:01:11.516Z","phase":"Phase 3","brief_title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","source_id_and_acronym":"NCT02970318 - ASCEND","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD5 • FCER2","pipe":" | ","alterations":" CD20 positive","tags":["CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib) • Zydelig (idelalisib) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 09/03/2021","primary_completion_date":" 09/03/2021","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-19"},{"id":"be1f4791-7f5f-42b3-86ee-a6bfee99acee","acronym":"ASSURE","url":"https://clinicaltrials.gov/study/NCT04008706","created_at":"2021-01-18T19:41:49.844Z","updated_at":"2025-02-25T14:07:28.508Z","phase":"Phase 3","brief_title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","source_id_and_acronym":"NCT04008706 - ASSURE","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • CD20 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • IGH mutation","tags":["TP53 • CD20 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 552","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-17"},{"id":"7aa05467-0129-42a5-a27e-e92acdec8860","acronym":"","url":"https://clinicaltrials.gov/study/NCT03701282","created_at":"2021-01-18T18:08:23.751Z","updated_at":"2025-02-25T15:43:14.904Z","phase":"Phase 3","brief_title":"Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT03701282","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 05/07/2028","primary_completion_date":" 05/07/2028","study_txt":" Completion: 05/07/2028","study_completion_date":" 05/07/2028","last_update_posted":"2025-02-10"},{"id":"ebb921a0-be62-4f58-b2bf-73010372d9d7","acronym":"A041702","url":"https://clinicaltrials.gov/study/NCT03737981","created_at":"2021-01-18T18:18:31.892Z","updated_at":"2025-02-25T15:34:13.549Z","phase":"Phase 3","brief_title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT03737981 - A041702","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 454","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-10"},{"id":"33da474f-b112-4a34-ad2b-bf3aa8c54e06","acronym":"AALL1231","url":"https://clinicaltrials.gov/study/NCT02112916","created_at":"2021-01-18T09:46:35.591Z","updated_at":"2025-02-25T16:51:23.270Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT02112916 - AALL1231","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 847","initiation":"Initiation: 10/04/2014","start_date":" 10/04/2014","primary_txt":" Primary completion: 03/31/2020","primary_completion_date":" 03/31/2020","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-04"},{"id":"93cce817-ed7e-442e-95cd-47f76d702a46","acronym":"","url":"https://clinicaltrials.gov/study/NCT02159755","created_at":"2021-01-18T10:03:07.008Z","updated_at":"2025-02-25T16:51:23.872Z","phase":"Phase 1","brief_title":"Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma","source_id_and_acronym":"NCT02159755","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CCND1 • CD5","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 06/25/2018","primary_completion_date":" 06/25/2018","study_txt":" Completion: 01/20/2026","study_completion_date":" 01/20/2026","last_update_posted":"2025-02-04"},{"id":"a5f14953-ab61-4581-b513-a86ad8a1e2b8","acronym":"AALL0434","url":"https://clinicaltrials.gov/study/NCT00408005","created_at":"2021-01-17T17:29:32.376Z","updated_at":"2025-02-25T16:50:52.092Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT00408005 - AALL0434","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1895","initiation":"Initiation: 01/22/2007","start_date":" 01/22/2007","primary_txt":" Primary completion: 09/30/2017","primary_completion_date":" 09/30/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"f4117edd-dc3b-4901-a803-80f17bc9e556","acronym":"","url":"https://clinicaltrials.gov/study/NCT05110742","created_at":"2021-11-08T23:20:11.943Z","updated_at":"2025-02-25T17:31:01.725Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances","source_id_and_acronym":"NCT05110742","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD5","pipe":"","alterations":" ","tags":["CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/22/2024","start_date":" 04/22/2024","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2025-01-30"},{"id":"12facf0a-d9fd-4fd1-aec9-b451aa677d4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06647940","created_at":"2025-02-26T09:23:18.118Z","updated_at":"2025-02-26T09:23:18.118Z","phase":"Phase 2","brief_title":"Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）","source_id_and_acronym":"NCT06647940","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD5","pipe":"","alterations":" ","tags":["CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Inokai (orelabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-10-22"},{"id":"ed362182-add1-434a-b6df-44f932cad804","acronym":"","url":"https://clinicaltrials.gov/study/NCT02135133","created_at":"2021-01-18T09:54:33.334Z","updated_at":"2025-02-25T13:11:11.926Z","phase":"Phase 2","brief_title":"A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL","source_id_and_acronym":"NCT02135133","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD19 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD19 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zydelig (idelalisib) • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 10/06/2020","primary_completion_date":" 10/06/2020","study_txt":" Completion: 10/06/2020","study_completion_date":" 10/06/2020","last_update_posted":"2024-10-16"},{"id":"259ce71b-5eef-4e8b-8117-2864d12c696a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01472562","created_at":"2021-01-18T06:08:26.175Z","updated_at":"2025-02-25T14:33:09.941Z","phase":"Phase 2","brief_title":"Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT01472562","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD20 • CCND1 • CD5 • CCND2 • MME • FCER2","pipe":" | ","alterations":" CCND1 overexpression • CCND2 overexpression","tags":["CD20 • CCND1 • CD5 • CCND2 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression • CCND2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 07/29/2011","start_date":" 07/29/2011","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 07/30/2023","study_completion_date":" 07/30/2023","last_update_posted":"2024-07-16"},{"id":"aa10c497-874a-4e78-b3a1-858e57d57b8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198650","created_at":"2021-01-18T15:46:19.909Z","updated_at":"2024-07-02T16:34:27.508Z","phase":"Phase 1","brief_title":"A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies","source_id_and_acronym":"NCT03198650","lead_sponsor":"AstraZeneca","biomarkers":" CD20 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 06/27/2017","start_date":" 06/27/2017","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2024-06-11"},{"id":"65f11ba4-54ff-43fd-a6f2-54316429b85b","acronym":"ECOG-ACRIN E1912","url":"https://clinicaltrials.gov/study/NCT02048813","created_at":"2021-01-17T17:35:11.745Z","updated_at":"2024-07-02T16:34:37.153Z","phase":"Phase 3","brief_title":"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT02048813 - ECOG-ACRIN E1912","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CCND1 • IGH • CD4 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CD4 positive","tags":["CD20 • CCND1 • IGH • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • cyclophosphamide • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 529","initiation":"Initiation: 02/20/2014","start_date":" 02/20/2014","primary_txt":" Primary completion: 10/24/2018","primary_completion_date":" 10/24/2018","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-07"},{"id":"6f307756-0908-4621-b9f3-65923112cc09","acronym":"SHINE ","url":"https://clinicaltrials.gov/study/NCT01776840","created_at":"2021-01-18T07:50:07.776Z","updated_at":"2024-07-02T16:34:37.245Z","phase":"Phase 3","brief_title":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01776840 - SHINE ","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 523","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-06-07"},{"id":"8de268c6-da6c-4e99-84fd-668feff0456e","acronym":"ALLIANCE A041202","url":"https://clinicaltrials.gov/study/NCT01886872","created_at":"2021-01-17T17:18:59.159Z","updated_at":"2024-07-02T16:34:37.292Z","phase":"Phase 3","brief_title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01886872 - ALLIANCE A041202","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 547","initiation":"Initiation: 12/09/2013","start_date":" 12/09/2013","primary_txt":" Primary completion: 08/07/2018","primary_completion_date":" 08/07/2018","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2024-06-07"},{"id":"d2401e9e-4fcb-4143-a93d-a94dce3674a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939272","created_at":"2021-06-25T22:54:05.033Z","updated_at":"2024-07-02T16:34:58.910Z","phase":"Phase 1/2","brief_title":"Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04939272","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2 • CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • PAX5 overexpression","tags":["BCL2 • CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • PAX5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 11/23/2024","primary_completion_date":" 11/23/2024","study_txt":" Completion: 11/23/2024","study_completion_date":" 11/23/2024","last_update_posted":"2024-06-04"},{"id":"06e22114-2e9b-44ef-aeef-5965af238d91","acronym":"","url":"https://clinicaltrials.gov/study/NCT06014762","created_at":"2023-08-28T14:08:43.980Z","updated_at":"2024-07-02T16:34:59.518Z","phase":"Phase 1","brief_title":"P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies","source_id_and_acronym":"NCT06014762","lead_sponsor":"Poseida Therapeutics, Inc.","biomarkers":" CD20 • CD5 • FCER2","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RG6540 • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/16/2024","start_date":" 04/16/2024","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2041","study_completion_date":" 03/01/2041","last_update_posted":"2024-06-03"},{"id":"2a05375a-5452-4690-a731-769e2628d4de","acronym":"TRANSCEND-CLL-004","url":"https://clinicaltrials.gov/study/NCT03331198","created_at":"2021-01-18T16:27:01.921Z","updated_at":"2024-07-02T16:34:59.670Z","phase":"Phase 1/2","brief_title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT03331198 - TRANSCEND-CLL-004","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" PLCG2 • CD5","pipe":" | ","alterations":" CD19 positive • PLCG2 mutation","tags":["PLCG2 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • PLCG2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 209","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 11/26/2027","primary_completion_date":" 11/26/2027","study_txt":" Completion: 11/26/2027","study_completion_date":" 11/26/2027","last_update_posted":"2024-05-31"},{"id":"6dc76f3c-ed63-4771-a0a4-3ac73d6fddbc","acronym":"ELEVATE-TN","url":"https://clinicaltrials.gov/study/NCT02475681","created_at":"2021-01-17T17:35:21.456Z","updated_at":"2024-07-02T16:35:00.298Z","phase":"Phase 3","brief_title":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL","source_id_and_acronym":"NCT02475681 - ELEVATE-TN","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD20 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib) • Leukeran (chlorambucil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 535","initiation":"Initiation: 06/26/2015","start_date":" 06/26/2015","primary_txt":" Primary completion: 02/08/2019","primary_completion_date":" 02/08/2019","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-29"}]